ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
- Disease/Condition
- Covid19
- Drug/Device/Intervention
- Fluvoxamine
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Susanna Naggie, MD
- Funder
- Duke University
- Location
- Gilbert,Mesa,Peoria,Newport Beach,North Hollywood,Palo Alto,Colorado Springs,Colorado Springs,Stamford,Washington,Deerfield Beach,Gainesville,Gainesville,Hialeah,Jacksonville,Jacksonville,Lake Mary,La, United States of America
- Phase
- Phase 3
- Start date
- Aug 25, 2022
- End date
- May 30, 2023
- Enrollment
- 1188 participants
Time to sustained recovery in Days
The purpose of this study is to evaluate the effectiveness of repurposed medications (study
 drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
 Participants will receive either study drug or placebo. They will self-report any new or
 worsening symptoms or medical events they may experience while taking study drug or placebo.
 This study is intended to be all remote with no in person visits, unless the study team feels
 it is in the best interest of a participant to see them in person.
 
 Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the
 activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov
 entry and will include Pro00107921 in the Unique Protocol ID.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05894564
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05894564 through Pure Global AI's free database. This Phase 3 trial is sponsored by Susanna Naggie, MD and is currently Completed. The study focuses on Covid19. Target enrollment is 1188 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.